L-Norvaline
Amino Acids 2025-03-20
L-Norvaline: A Comprehensive Overview
1. Chemical & Structural Profile
| Attribute | Details |
|---|---|
| Formula | C₅H₁₁NO₂ |
| Molar Mass | 117.15 g/mol |
| Classification | Non-proteinogenic α-amino acid; structural analog of L-Valine |
| Key Feature | Branched-chain aliphatic structure with terminal amino group |
2. Biological Activity & Mechanisms
| Function | Action |
|---|---|
| Arginase Inhibition | Competitively blocks arginase, increasing arginine bioavailability for NO synthesis |
| Vasodilatory Effect | Enhances endothelial NO production, promoting vasorelaxation |
| Metabolic Role | Modulates urea cycle efficiency; studied in ammonia detoxification pathways |
3. Therapeutic Implications
| Application | Evidence Base |
|---|---|
| Cardiovascular | Preclinical studies show improved endothelial function in hypertensive models |
| Erectile Dysfunction | Phase II trials suggest efficacy as phosphodiesterase-5 inhibitor adjunct |
| Exercise Performance | Limited research indicates potential to enhance muscle pump via vasodilation |
4. Dosage & Considerations
| Parameter | Guidelines |
|---|---|
| Typical Dose | 100-500 mg/day (varies by indication) |
| Administration | Oral capsules/tablets with meals for bioavailability |
| Contraindications | Pregnancy/lactation caution; monitor in renal impairment |
| Drug Interactions | May potentiate nitrates/sildenafil; avoid with arginine supplements |
